In the hyper-competitive San Francisco biotech scene, AfaSci is playing a different game entirely. While others chase unicorn valuations and media blitzes, this 18-person operation is quietly building a $2.8M revenue engine on pure substance over style.

"AfaSci proves you don't need a flashy website or massive funding to build a sustainable biopharma business."

The real story here is operational discipline. Eighteen people generating $2.8M means every team member is mission-critical. No bloat, no vanity metrics. Their Zendesk implementation signals they're actually supporting customers, not just collecting emails. This is a biotech that treats itself like a business, not a fundraising vehicle.

• Revenue-per-employee of $155K beats most early-stage startups
• Zero funding disclosed = potentially bootstrapped or quietly profitable
• Direct traffic dominance suggests strong B2B relationships
• Minimal web presence = focus on product, not marketing